RegCell is a novel therapeutics company that offers medical treatment to patients using regulatory T cells.
RegCell has raised $37.3M in total funding. The most recent round was Grant. The last funding was announced in March 2025.
RegCell's investors include Mitsubishi UFJ Capital, Nissay Capital, UTEC - The University of Tokyo Edge Capital Partners, Fast Track Initiative, Inc., Kyoto University Innovation Capital.
RegCell is headquartered in Osaka, Japan.
RegCell is a novel therapeutics company that offers medical treatment to patients using regulatory T cells.
RegCell is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RegCell — Funding & Investors." VCBacked, March 18, 2025, https://www.vcbacked.co/company/regcell. Accessed July 20, 2026.
VCBacked. (2025). RegCell — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/regcell
{{cite web |title=RegCell — Funding & Investors |url=https://www.vcbacked.co/company/regcell |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated